The Role of Interleukin-12 in Preserving the Graft-Versus-Leukemia Effect of Allogeneic CD8 T Cells Independently of GVHD

References

• Mortin M. M., Horowitz M. M., Rimm A. A. Increasing utilization of allogeneic bone marrow transplantation. III. Results of the 1988–1990 survey. Ann. Intern. Med. 1992; 116: 505–512
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Appelbaum F. R., Fisher L. D., Schoch G., Shulman H., Anasetti C., Bensinger W. I., Bryant E., Buckner C. D., Doney K., Martin P. J., Sanders J. E., Sullivan K. M., Thomas E. D., Witherspoon R. P., Hansen J. A., Storb R. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677–681
   PubMed Web of Science ®Google Scholar
• Beatty P. G., Anasetti C., Hansen J. A., Longton G. M., Sanders J. E., Martin P. J., Mickelson E. M., Choo S. Y., Petersdorf E. W., Pepe M. S., Appelbaum F. R., Bearman S. I., Buckner C. D., Clift R. A., Petersen F. B., Singer J., Stewart P. S., Storb R. F., Sullivan K. M., Tesler M. C., Witherspoon R. P., Thomas E. D. Marrow transplantation from unrelated donors for treatment of hemato‐logic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81: 249–253
   PubMed Web of Science ®Google Scholar
• Eibl B., Schwaighofer H., Nachbaur D., Marth C., Gachter A., Knapp R., Bock G., Gassner C., Schiller L., Petersen F., Niederwieser D. Evidence for a graft‐versus‐tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501–1508
   PubMed Web of Science ®Google Scholar
• Kolb H. ‐J., Schattenberg A., Goldman J. M., Hertenstein B., Jacobsen N., Arcese W., Ljungman P., Ferrant A., Verdonck L., Niederwieser D., van Rhee F., Mittermuel‐ler J., de Witte T., Holler E., Ansari H. Graft‐versus‐leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–2050
   PubMed Web of Science ®Google Scholar
• Beatty P. G., Clift R. A., Mickelson F. M., Nisperos B. B., Flournoy N., Martin P. J., Sanders J. E., Stewart P., Buckner C. D., Storb R., Thomas E. D., Hansen J. A. Marrow transplantation from related donors other than HLA‐identical siblings. N. Engl. J. Med. 1985; 313: 765–771
   PubMed Web of Science ®Google Scholar
• Bortin M. M. Bone marrow transplantation for leukemia using family donors other than HLA‐identical siblings: a preliminary report from the International Bone Marrow Transplant Registry. Transplant. Proc. 1987; 19: 2629–2631
   PubMed Web of Science ®Google Scholar
• Sierra J., Storer B., Hansen J. A., Bjerke J. W., Martin P. J., Petersdorf E. W., Appelbaum F. R., Bryant E., Chauncey T. R., Sale G., Sanders J. E., Storb R., Sullivan K. M., Anasetti C. Transplantation marrow cells from unrelated donor for treatment of high‐risk acute leukemia: The effect of leukemic burden, donor HLAmatch‐ing, and marrow cell dose. Blood 1997; 89: 4226–4235
   PubMed Web of Science ®Google Scholar
• Verdonck L. F., Dekker A. W., Lokhorst H. M., Petersen E. J., Nieuwenhuis H. K. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low‐grade Non‐hodgkin's lymphoma. Blood 1997; 90: 4201–4205
   PubMed Web of Science ®Google Scholar
• Gale R. P. Graft‐versus‐host disease. Immunologic Rev 1985; 88: 193–214
   PubMed Web of Science ®Google Scholar
• Ringden O., Nilsson B. Death by graft‐versus‐host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985; 40: 39–44
   PubMed Web of Science ®Google Scholar
• Lokhorst H. M., Schattenberg A., Cornelissen J. J., Thomas L. L. M., Verdonck L. F. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206–4211
   PubMed Web of Science ®Google Scholar
• Uharek L., Glass B., Gaska T., Zeiss M., Gassmann W., Loffler H., Muller Ruchholtz W. Natural killer cells as effector cells of graft‐versus‐leukemia activity in a murine transplantation model. Bone Marrow Transplant. 1993; 12: S57–60, 57–60
   PubMed Web of Science ®Google Scholar
• Zeis M., Uharek L., Glass B., Gaska T., Steinmann J., Gassman W., Loffler H., Muller‐Ruchholtz W. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 1995; 59: 1734–1736
   PubMed Web of Science ®Google Scholar
• Asai O., Longo D. L., Tian R. L., Taub D. D., Ruscetti F. W., Murphy W. J. Suppression of graft‐versus‐host disease and amplification of graft‐versus‐tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J. Clin. Invest. 1998; 101: 1835–1842
   PubMed Web of Science ®Google Scholar
• Papadopoulos E. B., Carabasi M. H., Castro‐Malaspina H., Childs B. H., Mackinnon S., Boulad F., Gillio A. P., Ker‐nan N. A., Small T. N., Szabolcs P., Taylor J., Yahalom J., Collins N. H., Bleau S. A., Black P. M., Heller G., O'Reilly R. J., Young J. W. T‐cell‐depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft‐versus‐host disease. Blood 1998; 91: 1083–1090
   PubMed Web of Science ®Google Scholar
• Soiffer R. J., Fairclough D., Robertson M., Alyes E., Anderson K., Freedman A., Bartlett‐pandite L., Fisher D., Schlossman R. L., Stone R., Murray C., Marcus K., Mauch P., Nadler L., Ritz J. CD6‐depleted allogeneic bone marrow transplantation for leukemia in first complete remission. Blood 1997; 89: 3039–3047
   PubMed Web of Science ®Google Scholar
• Martin P. J., Hansen J. A., Torok‐Storb B., Durnam D., Przepiorka D., O'Quigley J., Sanders J., Sullivan K. M., Witherspoon R. P., Deeg H. J., Appelbaum F. R., Stewart P., Weiden P., Doney K., Buckner C. D., Clift R., Storb R., Thomas E. D. Graft failure in patients receiving T cell‐depleted HLA‐identical allogeneic marrow transplants. Bone Marrow Transplant. 1988; 3: 445–456
   PubMed Web of Science ®Google Scholar
• Poynton C. H. T cell depletion in bone marrow transplantation. Bone Marrow Transplant. 1988; 3: 265–279
   PubMed Web of Science ®Google Scholar
• Butturini A., Gale R. P. T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant. 1988; 3: 185–192
   PubMed Web of Science ®Google Scholar
• Slavin S., Ackerstein A., Naparstek E., Or R., Weiss L. The graft‐versus‐leukemia (GVL). phenomenon: is GVL separable from GVHD?. Bone Marrow Transplant. 1990; 6: 155–161
   PubMed Web of Science ®Google Scholar
• Sykes M. Novel approaches to the control of GVHD. Curr. Opin. Immunol. 1993; 5: 774–781
   PubMed Web of Science ®Google Scholar
• Uharek L., Glass B., Zeis M., Dreger P., Steinmann J., Loffler H., Schmitz N. Abrogation of graft‐vs.‐leukemia activity after depletion of CD3+ T cells in a murine model of MHC‐matched peripheral blood progenitor cells. Exp. Hematol. 1998; 26: 93–99
   PubMed Web of Science ®Google Scholar
• Blazar B. R., Taylor P. A., Panoskaltsis‐Mortari A., Vallera D. A. Rapamycine inhibits the generation of graft‐versus‐host disease‐ and graft‐versusleuke‐mia‐causing T cells by interfering with the production of Thl or Thl cytotoxic cytokines. J. Immunol. 1998; 160: 5355–5365
   PubMed Web of Science ®Google Scholar
• Sykes M., Szot G. L., Nguyen P. L., Pearson D. A. Interleukin‐12 inhibits murine graft‐vs‐host disease. Blood 1995; 86: 2429–2438
   PubMed Web of Science ®Google Scholar
• Yang Y. ‐G., Sergio J. J., Pearson D. A., Szot G. L., Shimizu A., Sykes M. Interleukin‐12 preserves the graft‐vs‐leukemia effect of allogeneic CD8 T cells while inhibiting CD4‐dependent graft‐vs‐host disease in mice. Blood 1997; 90: 4651–4660
   PubMed Web of Science ®Google Scholar
• Nash R. A., Storb R. Graft‐versus‐host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL. Cur. Opin. Immunol. 1996; 8: 674–680
   PubMed Web of Science ®Google Scholar
• Glass B., Uharek L., Zeis M., Dreger P., Loffler H., Steinmann J., Schmitz N. Allogeneic blood progenitor cell transplantation in murine model: evidence for an improved graft‐versus‐leukemia effect. Blood 1997; 90: 1694–1700
   PubMed Web of Science ®Google Scholar
• Fowler D. H., Kurasawa K., Smith R., Eckhaus M. A., Gress R. E. Donor CD4‐enriched cells of Th2 cytokine phenotype regulate graft‐versus‐host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540–3549
   PubMed Web of Science ®Google Scholar
• Aizawa S., Sado T. Graft‐versus‐leukemia effect in MHC‐compatible andincompatible allogeneic bone marrow transplantation of radiation‐induced, leuke‐miabearing mice. Transplantation 1991; 52: 885–889
   PubMed Web of Science ®Google Scholar
• Fowler D. H., Breglio J., Nagel G., Eckhaus M. A., Gress R. E. Allospecific CD8+ Tcl and Tc2 population in graft‐vs‐leukemia effect and graft‐vs‐host disease. J. Jmmunol. 1996; 157: 4811–4821
   PubMed Web of Science ®Google Scholar
• Okunewick J. P., Kociban D. L., Machen L. L., Buffo M. J. The role of CD4 and CD8 T cells in the graft‐versus‐leukemia response in Rauscher murine leukemia. Bone Marrow Transplant. 1991; 8: 445–452
   PubMed Web of Science ®Google Scholar
• Sykes M., Harty M. W., Szot G. L., Pearson D. A. Interleukin‐2 inhibits graft‐versus‐host disease‐promating activity of CD4+ cells while preserving CD4– and CD8‐mediated graft‐versus‐leukemia effects. Blood 1994; 83: 2560–2569
   PubMed Web of Science ®Google Scholar
• Giralt S., Hester J., Hirscb‐Ginsberg C., Rondon G., Seong D., Lee M., Gajewski J., Van Besien K., Khouri I., Mehra R., Przepiorka D., Korbling M., Talpdz M., Kantarjian H., Deisser A., Champlin R. CD8‐depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337–4343
   PubMed Web of Science ®Google Scholar
• Claret E. J., Alyea E. P., Orsini E., Pickett C. C., Collins H., Wany Y., Soiffer R. J., Ritz J. Characterization of T cell repertoire in patients with graft‐versus‐leukemia after donor lymphocyte infusion. J. Chn. Invest. 1998; 100: 855–866
   Web of Science ®Google Scholar
• Rocha M., Umansky V., Lee K. ‐H., Hacker H. ‐J., Ben‐ner A., Schirrmacher V. Differences between graft‐versus‐leukemia and graft‐versus‐host reactivity. I. Interaction of donor immune T cells with tumor and/or host cells. Blood 1997; 89: 2189–2202
   PubMed Web of Science ®Google Scholar
• Dolstra H., Fredrix H., Preijers F., Goulmy E., Figdor C. G., de Witte T. M., van de Weil‐van Kenienade E. Recognition of a B cell leukemia‐associated minor histocompatibility antigen by CTL. J. Immunology 1997; 158: 560–565
   PubMed Web of Science ®Google Scholar
• Bonini C., Ferrari G., Verzeletti S., Servida P., Zappone E., Ruggieri L., Ponzoni M., Rossini S., Mavilio F., Tra‐versari C., Bordignon C. HSV‐TK gene transfer into donor lymphocytes for control of allogeneic graft‐versus‐leukemia. Science 1997; 276: 1719–1724
   PubMed Web of Science ®Google Scholar
• Cohen J. L., Boyer O., Salomon B., Onclercq R., Charlotte F., Bruel S., Boisserie G., Klatzmann D. Prevention of graft‐versus‐host disease in mice using a suicide gene expressed in T lymphocytes. Blood 1997; 89: 4636–4645
   PubMed Web of Science ®Google Scholar
• Munshi N. C., Govindarajan R., Drake R., Ding L. M., Lyer R., Saylors R., Kombluth J., Marcus S., Ennist D., Kwak L., Reynolds C., Tricot G., Barlogie B. Thymidine Kinase (TK) gene‐transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 1997; 89: 1334–1340
   PubMed Web of Science ®Google Scholar
• Sykes M., Sheard M. A., Sachs D. H. Graft‐ver‐sus‐host‐related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lym‐phohematopoietic cells. J. Exp. Med. 1988; 168: 2391–2396
   PubMed Web of Science ®Google Scholar
• D'Andrea A., Rengaraju M., Valiante N. M., Chehimi J., Aste‐Amezaga M., Chen S. H., Kobayashi M., Young D., Nickbarg E., Chizzonite R., Wolf S. F., Trinchieri G. Production of natural killer cell stimulatory factor interleukin 12 by peripheral blood mononuclear cells. J. Exp. Med. 1992; 176: 1387–1398
   PubMed Web of Science ®Google Scholar
• Manetti R., Parronchi P., Giudizi M. G., Piccini M. ‐P., Maggi E., Trinchieri G., Romagnani S. Natural killer cell stimulatory factor (Interleukin 12 [IL‐12]) induces T helper type 1 (Th1)‐specific immune responses and inhibits the development of IL‐4‐producing Th cells. J. Exp. Med. 1993; 177: 1199–1204
   PubMed Web of Science ®Google Scholar
• Kobayashi M., Fitz L., Ryan M., Hewick R. M., Clark S. C., Chan S., Ludon R., Sherman F., Perussia B., Trinchieri G. Identification and purification of natural killer stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 1989; 170: 827–835
   PubMed Web of Science ®Google Scholar
• Chouaib S., Chehimi J., Bani L., Genetet N., Tursz T., Gay E., Trinchieri G., Mami‐Chouaib F. Interleukin‐12 induces the differentiation of major histocompatibility complex class I‐primed cytotoxic T‐lymphocyte precursors into allospecific cytotoxic effectors. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 12659–12663
   PubMed Web of Science ®Google Scholar
• Seder R. A., Gazzinelli R., Sher A., Paul W. E. Interleukin‐12 acts directly on CD4+ T cells to enhance priming for interferon‐gamma production and diminishes interleukin‐4 inhibition of such priming. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 10188–10192
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin‐12 and its role in the generation of Thl cells. Immunol. Today 1993; 14: 335–338
   PubMedGoogle Scholar
• Brunda M. J., Luistro L., Warrier R. R., Wright R. B., Hubbard B. R., Murphy M., Wolf S. F., Gately M. K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 1993; 178: 1223–1230
   PubMed Web of Science ®Google Scholar
• Hashimoto W., Takeda K., Anzai R., Ogasawwa K., Sak‐ihara H., Sugiura K., Seki S., Knmagai K. Cytotoxic NKI. 1 Ag+ αβ T cells with intermediate TCR induced in the liver of mice by IL‐12. J. Immunol. 1995; 154: 4333–4340
   PubMed Web of Science ®Google Scholar
• Nogucbi Y., Jungbluth A., Richards E. C., Old L. J. Effect of interleukin 12 on tumor induction by 3‐methylcholanthrene. Proc. Natl. Acad. Sci. USA 1996; 93: 11798–11801
   PubMed Web of Science ®Google Scholar
• Cui J., Shin T., Kawano T., Sato H., Kondo E., Toura I., Kaneko Y., Koseki H., Kanno M., Taniguchi M. Requirement for Vα14 NKT cells in IL‐12mediated rejection of tumors. Science 1997; 278: 1623–1626
   PubMed Web of Science ®Google Scholar
• Via C. S., Rus V., Gately M. K., Finkelman F. D. IL‐12 stimulates the development of acute graft‐versus‐host disease in mice that normally would develop chronic, autoimmune graft‐versus‐host disease. J. Immunol. 1994; 153: 4040–4047
   PubMed Web of Science ®Google Scholar
• Williamson E., Garside P., Bradley J. A., Mowat A. M. IL‐12 is a central mediator of acute graft‐versus‐host disease in mice. J. Jmmunol. 1996; 157: 689–699
   PubMed Web of Science ®Google Scholar
• Williamson E., Garside P., Bradley J. A., More I. A. R., Mowat A. M. Neutralizing IL‐12 during induction of murine acute graft‐versus‐host disease polarizes the cytokine profile toward a Th2‐type alloimmune response and confers long term protection from disease. J. Immunol. 1997; 159: 1208–1215
   PubMed Web of Science ®Google Scholar
• Yang Y. ‐G., Dey B., Sergio J. J., Sykes M. IL‐12 prevents severe acute GVHD and GVHD‐associated immune dysfunction in a full MHC haplotype‐mismatched murine bone marrow transplantation model. Transplantation 1997; 64: 1343–1352
   PubMed Web of Science ®Google Scholar
• Dey B., Yang Y. ‐G., Szot G. L., Pearson D. A., Sykes M. IL‐12 inhibits GVHD through a Fas‐mediated mechanism associated with alterations in donor T cell activation and expansion. Blood 1998; 91: 3315–3322
   PubMed Web of Science ®Google Scholar
• Moser M., Iwasaki T., Shearer G. M. Cellular interactions in graft‐versus‐host ‐induced T cell immune deficiency. Immunol. Rev 1985; 88: 135–151
   PubMed Web of Science ®Google Scholar
• Lapp W. S., Ghayur T., Mendes M., Seddik M., Seemayer T. A. The functional and histological basis for graft‐versus‐host‐induced immunosuppression. Immunologic Rev 1985; 88: 107–131
   PubMed Web of Science ®Google Scholar
• Gleichmann H., Gleichmann E., Andre‐Schwartz J., Schwartz R. S. Chronic allogeneic disease. III. Genetic requirements for the induction of glomerulonephri‐tis. J Exp. Med. 1972; 135: 516–532
   PubMed Web of Science ®Google Scholar
• Reap E. A., Sovel E. S., Jennette J. C., Cohen P. L., Eisenberg R. A. Conventional B cells, not B 1 cells, are the source of autoantibodies in chronic graft‐versus‐host disease. J. Immunol. 1993; 151: 7316–7323
   PubMed Web of Science ®Google Scholar
• Via C. S., Shearer G. M. Murine graft‐versus‐host disease as a model for the development of autoim‐munity. Relevance of cytotoxic T lymphocytes. Ann. N. Y. Acad. Sci. 1988; 532: 44–50
   PubMed Web of Science ®Google Scholar
• Morris S. C., Cheek R. L., Cohen P. L., Eisenberg R. A. Autoantibodies in chronic graft versus host result from cognate T‐B interactions. J Exp. Med. 1990; 171: 503517
   Web of Science ®Google Scholar
• Desbarats J., Lapp W. S. Thymic selection and thymic major histocompatibility complex class II expression are abnormal in mice undergoing graft‐versus‐host reactions. J. Exp. Med. 1993; 178: 805–814
   PubMed Web of Science ®Google Scholar
• Hollander G. A., Widmer B., Burakoff S. J. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J. Immunol. 1994; 152: 1609–1617
   PubMed Web of Science ®Google Scholar
• Moser M., Mizuochi T., Sharrow S. O., Singer A., Shearer G. M. Graft‐versus‐host reaction limited to a class II difference results in a selective deficiency in L3T4+ but not in Lyt‐2+ T helper cell function. J. Immunol 1987; 138: 1355–1362
   PubMed Web of Science ®Google Scholar
• Via C. S., Sharrow S. O., Shearer G. M. Role of cytotoxic T lymphocytes in the prevention of lupus‐like disease occurring in a murine model of graft‐vs‐host disease. J. Immunol. 1987; 139: 1840–1849
   PubMed Web of Science ®Google Scholar
• Ghayur T., Seemayer T. A., Xenocostas A., Lapp W. S. Complete sequential regeneration of graft‐vs. ‐host induced severely dysplastic thymuses. Am. J. Pathol. 1988; 133: 39–46
   PubMed Web of Science ®Google Scholar
• Wienberg K., Annett G., Kashyap A., Lenarsky C., For‐man S. J., Parkman R. The effect of thymic function on immunocompetence following bone marrow transplantation. Biol Blood Marrow Transplant 1995; 1: 18–23
   PubMedGoogle Scholar
• Gately M. K., Desai B. B., Wolitzky A. G., Quinn P. M., Dwyer C. M., Podlaski F. J., Familletti P. C., Sinigaglia F., Chizonnite R., Gubler U., Stem A. S. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL‐12 (cytotoxic lymphocyte maturation factor). J. Immunol. 1991; 147: 874–882
   PubMed Web of Science ®Google Scholar
• Mehrotra P. T., Wu D., Crim J. A., Mostowki H. S., Siegel J. P. Effects of IL‐12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J. Immunol. 1993; 151: 2444–2452
   PubMed Web of Science ®Google Scholar
• Orange J. S., Wolf S. F., Biron C. A. Effects of IL‐12 on the response and susceptibility to experimental viral infections. J. Immunol. 1994; 152: 1253–1264
   PubMed Web of Science ®Google Scholar
• Sykes M., Bukhari Z., Sachs D. H. Graft‐ver‐sus‐leukemia effect using mixed allogeneic bone marrow transplantation. Bone Marrow Transplant. 1989; 4: 465–474
   PubMed Web of Science ®Google Scholar
• Sykes M., Romick M. L., Sachs D. H. Interleu‐kin 2 prevents graft‐vs‐host disease while preserving the graft‐vs‐leukemia effect of allogeneic T cells. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 5633–5637
   PubMed Web of Science ®Google Scholar
• Sykes M., Abraham V. S., Harty M. W., Pearson D. A. IL‐2 reduces graft‐vs‐host disease and preserves a graft‐vs‐leukemia effect by selectively inhibiting CD4+ T cell activity. J. Immunol. 1993; 150: 197–205
   PubMed Web of Science ®Google Scholar
• Pietryga D., Blazar B. R., Soderling C. B., Vallera D. A. The effect of T subset depletion on the incidence of lethal graft‐versus‐host disease in a murine majorhistocompatibility‐complex‐mismatched transplantation system. Transplantation 1987; 43: 442445
   Web of Science ®Google Scholar
• Korngold R., Sprent J. Surface markers of T cells causing lethal graft‐vs‐host disease to class I vs class II H‐2 differences. J. Immunol. 1985; 135: 3004–3010
   PubMed Web of Science ®Google Scholar
• Vallera D. A., Soderling C. C. B., Kersey J. H. Bone marrow transplantation across major histocompatihility barriers in mice. III. Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants. J. Immunol. 1982; 128: 871–875
   PubMed Web of Science ®Google Scholar
• Uenaka A., Mieno M., Kuribayashi K., Shiku H., Nakayama E. Effector cells of lethal graft‐versus‐host disease (GVHD). in nude mice. Transplant. Proc. 1989; 21: 3031–3032
   PubMed Web of Science ®Google Scholar
• Thiele D. L., Charley M. R., Calomeni J. A., Lipsky P. E. Lethal graft‐vs‐host disease across major histocompatibility barriers: requirement for leucyl‐leucine methyl ester sensitive cytotoxic T cells. J. Immunol. 1987; 138: 51–57
   PubMed Web of Science ®Google Scholar
• Szebeni J., Wang M. ‐G., Pearson D. A., Szot G. L., Sykes M. IL‐2 inhibits early increases in serum gamma interferon levels associated with graft‐vs‐host disease. Transplantation 1994; 58: 1385–1393
   PubMed Web of Science ®Google Scholar
• Niederwieser D., Herold M., Woloszczuk W., Aulitzky W., Meister B., Tilg H., Gastl G., Bowden R., Huber C. Endogenous IFN‐gamma during human bone marrow transplantation. Analysis of serum levels of inter‐feron and interferon‐dependent secondary messages. Transplantation. 1990; 50: 620–625
   PubMed Web of Science ®Google Scholar
• Allen R. D., Staley T. A., Sidman C. L. Differential cytokine expression in acute and chronic murine graft‐versus‐host disease. Eur. J. Immunol. 1993; 23: 333–337
   PubMed Web of Science ®Google Scholar
• Guy‐Grand D., Vassalli P. Gut injury in mouse graft‐vs‐host reaction: study of its occurrence and mechanism. J. Clin. Invest. 1986; 77: 1584–1595
   PubMed Web of Science ®Google Scholar
• Mowat A. M. Antibodies to IFN‐gamma prevent immunologically mediated intestinal damage in murine graft‐versus‐host reaction. Immunology 1989; 68: 18–23
   PubMed Web of Science ®Google Scholar
• Brok H. P. M., Heidt P. J., Van der Meide P. H., Zurcher C., Vossen J. M. Interferon‐gamma prevents graft‐versus‐host disease after allogeneic bone marrow transplantation in mice. J. Immunol. 1993; 151: 6451–6459
   PubMed Web of Science ®Google Scholar
• Wang M. ‐G., Szebeni J., Pearson D. A., Szot G. L., Sykes M. Inhibition of graft‐vs‐host disease (GVHD). by IL‐2 treatment is associated with altered cytokine production by expanded GVH‐reactive CD4+ helper cells. Transplantation 1995; 60: 481–490
   PubMed Web of Science ®Google Scholar
• Klimpel G. R., Annable C. R., Cleveland M. G., Jerrells T. R., Patterson J. C. Immunosuppression and lymphoid hypoplasia associated with chronic graft versus host disease is dependent upon IFN‐ gamma production. J. Immunol. 1990; 144: 84–93
   PubMed Web of Science ®Google Scholar
• Holda J. H., Maier T., Claman H. N. Evidence that IFN‐gamma is responsible for natural suppressor activity in GVHD spleen and normal bone marrow. Transplantation 1988; 45: 772–777
   PubMed Web of Science ®Google Scholar
• Wall D. A., Hamberg S. D., Reynolds D. S., Burakoff S. J., Abbas A. K., Ferrara J. L. M. Immunodeficiency in graft‐versus‐host disease. I. Mechanism of immune suppression. J. Immunol. 1988; 140: 2970–2976
   PubMed Web of Science ®Google Scholar
• Brok H. P., Vossen J. M., Heidt P. J. Inter‐feron‐gamma‐mediated prevention of graft‐versus‐host disease: development of immune competent and allo‐tolerant T cells in chimeric mice. Bone Marrow Transplant. 1997; 19: 601–606
   PubMed Web of Science ®Google Scholar
• Garvy B. A., Gigliotti F., Harmsen A. G. Neutralization of interferon‐gamma exacerbates pneumocys‐tis‐driven interstitial pneumonitis after bone marrow transplantation. J. Clin. Invest. 1997; 99: 1637–1644
   PubMed Web of Science ®Google Scholar
• Liu Y., Janeway C. A. Interferon‐gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self‐tolerance. J. Exp. Med. 1990; 172: 1735–1739
   PubMed Web of Science ®Google Scholar
• Novelli F., Di Pierro F., Francia di Celle P., Bertini S., Affaticati P., Garotta G., Fomi G. Environmental signals influencing expression of the IFN‐γ receptor on human T cells control whether IFN‐g promotes proliferation or apoptosis. J. Immunol. 1994; 152: 496–504
   PubMed Web of Science ®Google Scholar
• Novelli F., Bemabei P., Ozmen L., Rigamonti L., Allione A., Pestka S., Garotta G., Fomi G. Switching on of the proliferation or apoptosis of activated human T lyniphocytes by IFN‐γ is correlated with the differential expression of the α and β‐chains of its receptor. J. Immnunol. 1996; 157: 1935–1943
   PubMed Web of Science ®Google Scholar
• Novelli F., D'Elios M. M., Bernabei P., Ozmen L., Rigamonti L., Almerigogna F., Forni G., Del Prete G. Expression and role in apoptosis of the alpha‐ and beta‐chains of the IFN‐gamma receptor on human Th1 and Th2 clones. J. Immunol. 1997; 159: 206–213
   PubMed Web of Science ®Google Scholar
• Oyaizu N., McCloskey T. W., Than S., Hu R., Kalyanara‐man V. S., Pahwa S. Cross‐linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon‐gamma and tumor necrosis factor‐a secretion. Blood 1994; 84: 2622–2631
   PubMed Web of Science ®Google Scholar
• Konieczny B. T., Dai Z., Elwood E. T., Saleem S., Lins‐ley P. S., Baddoura F. K., Larsen C. P., Pearson T. C., Lakkis F. G. IFN‐γ is critical for long‐term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J. Immunol. 1998; 160: 2059–2064
   PubMed Web of Science ®Google Scholar
• Nastala C. L., Edington H. D., McKinney T. G., Tahara H., Nalesnik M. A., Brunda M. J., Getely M. K., Wolf S. F., Schreiber R. D., Storkus W. J., Lotze M. T. Recombinant IL‐12 administration induces tumor regression in association with IFN‐gamma production. J. Immunol. 1994; 153: 1697–1706
   PubMed Web of Science ®Google Scholar
• Brunda M. J., Sulich V., Bellantoni D. The anti‐tumor effect of recombinant interferon alpha and gamma is influenced by tumor location. Int. J. Cancer 1987; 40: 807–810
   PubMed Web of Science ®Google Scholar
• Sayers T. J., Wiltrout T. A., McCormick K., Wiltrout R. H. Antitumor effects of alpha‐interferon and gamma‐interferon on a murine renal cancer (Renca). in vitro and in vivo. Cancer Res. 1990; 50: 5414–5420
   PubMed Web of Science ®Google Scholar
• Tannenbaum C. S., Wicker N., Armstrong D., Tubbs R., Finke J., Bukowski R. M., Hamilton T. A. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL‐12. J. Immunol. 1996; 156: 693–699
   PubMed Web of Science ®Google Scholar
• Tan J., Crucian B. E., Chang A. E., Aruga A., Dovhey S. E., Tanigawa K., Yu H. Inter‐feron‐gamma‐inducing factor elicits antitumor immunity in association with interferon‐gamma production. J. Immu‐nother. 1998; 21: 48–55
   PubMed Web of Science ®Google Scholar
• Brunda M. J., Luistro L., Hendrzak J. A., Fountoulakis M., Garotta G., Gately M. K. Role of inter‐feron‐γ in mediating the antitumor efficacy of interleu‐kin‐12. J. Immunothes. 1995; 17: 71–77
   PubMed Web of Science ®Google Scholar
• Simon M. M., Hochgeschwender U., Brugger U., Landolfo S. Monoclonal antibodies to interferon‐gamma inhibit interleukin 2‐dependent induction of growth and maturation in lectin/antigen‐reactive cytolytic T lymphocyte precursors. J. Immunol. 1986; 136: 2755–2762
   PubMed Web of Science ®Google Scholar
• Zanovello P., Vallerani E., Biasi G., Landolfo S., Col‐lavo D. Monoclonal antibody against IFN‐gamma inhibits moloney murine sarcoma virus‐specific cytotoxic T lymphocyte differentiation. J Immunol. 1988; 140: 1341–1344
   PubMed Web of Science ®Google Scholar
• Sad S., Marcotte R., Mosmann T. R. Cytok‐ine‐induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells. Immunity 1995; 2: 271–279
   PubMed Web of Science ®Google Scholar